mg/100 ml) when TPTX mothers received 0.05 to 0.5 fL9/ kg, but decreased with higher doses. The highest fetal liver glycogen store (80 mg/g) was achieved using 0.05 fL9 of 1,25-(OH) 2 D 3/ kg, this increment being progressively inhibited when larger doses were given. Subcutaneous calcifications were observed in the fetuses of some litters after treatment of the TPTX mothers with 1 ¡.¡.9 of 1,25-(OH) 2 D 3/ kg.
Summary. Thyroparathyroidectomy (TPTX) in pregnant rats on day 12.5 of gestation was associated with a progressive reduction of dietary intake between days 18 and 21 of gestation. In control mothers with a similar dietary restriction, the fetal plasma calcium and phosphate levels were unchanged, and a slight decrease in fetal weight (! 0.8 g) was observed at term. Maternal hypocalcemia in TPTX animals induced chronic fetal hypocalcemia beginning at day 18.5 of gestation ; fetal hyperphosphatemia was only statistically significant on the last day of gestation. Weight, blood glucose and liver glycogen stores, which were greatly decreased in fetuses from untreated TPTX mothers, increased after injection of 1,25-(OH) 2 D 3 into TPTX mothers. A marked increase in fetal weight ( + 1.6-2.0 g) occurred at term with doses ranging from 0.05 to 0.25 [L g/kg of body weight ; higher doses (> 0.5 fL9/ kg) inhibited this improvement. Fetal blood glucose was normalized (-45-50 mg/100 ml) when TPTX mothers received 0.05 to 0.5 fL9/ kg, but decreased with higher doses. The highest fetal liver glycogen store (80 mg/g) was achieved using 0.05 fL9 of 1,25-(OH) 2 D 3/ kg, this increment being progressively inhibited when larger doses were given. Subcutaneous calcifications were observed in the fetuses of some litters after treatment of the TPTX mothers with 1 ¡.¡.9 of 1,25-(OH) 2 D 3/ kg.
Introduction.
Since it is known that rat fetuses from thyroparathyroidectomized (TPTX) mothers are characterized by reduced weight (Garel and Geloso-Meyer, 1971 ) and lower levels of plasma calcium, blood glucose and liver glycogen stores, whereas plasma phosphate levels increase (Porterfield, Whittle and Hendrich, 1975 ; Garel and Gilbert, 1978) , and that administration of 1,25-dihydroxyvitamin D a (1,25-(OH),D,) to these mothers recovers the values (Garel, Gilbert and Besnard, 1979 ; (Pic, 1969) . A drop in plasma calcium was observed at day 21.5 of gestation in control females with dietary restriction (-0.88 mg/100 ml ; P < 0.001). In TPTX mothers, plasma calcium was already significantly reduced on day 17.5 of gestation ; between days 19.5 and 21.5 of gestation, maternal plasma calcium remained constant at a low value : -4 mg/100 ml ( fig. 1) . Plasma phosphate levels in normal mothers were unchanged during the last five days of gestation, as found in an earlier study by Garel and Pic (1972) . In dietary control females, the plasma phosphate level was similar to that in the normal females. Plasma phosphate levels significantly increased 6 days after TPTX in the mothers (fig. 2) (fig. 2) ; however, the difference was only significant on the last day. Injecting 0.025 ¡.¡.g of 1,25-(OH) 2 D 3/ kg of body weight into TPTX mothers had no effect ( fig. 4) (Garel and Gilbert,1978 ; Gilbert, Besnard and Garel, 1980) . The use of larger doses reduced fetal weight, perhaps due to the toxic effects of 1,25-(OH) 2 D 3 or to chronic maternal and fetal hypercalcemia.
Decreases in maternal plasma calcium levels in TPTX mothers were paralleled by reduced fetal levels between days 17.5 and 19.5 of gestation, This decrease in the fetus might be related to the beginning of fetal ossification which occurs at day 17.5 of gestation (Comar, 1956 ; Jost, Moreau and Fournier, 1960 ; Chef, 1969) ; the amounts of calcium, transferred at the same time from the mother to the fetus, increased considerably (Comar, 1956 ; Chef, 1969) . Thus a sharp decrease in maternal plasma calcium level induced chronic fetal hypocalcemia (> 2 mg/100 ml).
We showed that a low dose of 1 ,25-(OH) 2 D a (0.05 gg /kg of body weight ; 30 picomoles per pregnant female) normalized fetal blood glucose and induced a 2.5-fold increase in fetal liver glycogen stores ; however, maternal plasma calcium remained low : 8.5 mg/100 ml. Whatever the maternal plasma calcium level, it appeared that both fetal blood glucose and liver glycogen levels were higher in 1,25-(OHhD 3 -treated TPTX mothers than in untreated TPTX mothers.
These data suggest that the fetal weight in TPTX mothers was somewhat dependent on maternal blood 1,25-(OH) 2 D 3 levels since we have shown that plasma 1,25-(OH) 2 D levels decrease in TPTX mothers on day 21.5 of gestation (Garel et al., 1981) . The requirements for 1,25-(OH),D, probably increase at the end of gestation ; the observation of elevated serum 1,25-(OH) 2 D a levels in pregnant rats at the end of gestation (Halloran, Barthell and de Luca, 1979 ; Pike et al., 1979 ; Garel et al., 1981) 
